QRG Capital Management Inc. Acquires 57,284 Shares of Takeda Pharmaceutical Co. (NYSE:TAK)

QRG Capital Management Inc. lifted its position in Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 17.4% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 386,928 shares of the company's stock after purchasing an additional 57,284 shares during the quarter. QRG Capital Management Inc.'s holdings in Takeda Pharmaceutical were worth $5,754,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the company. Sagespring Wealth Partners LLC purchased a new position in shares of Takeda Pharmaceutical in the first quarter valued at $162,000. Fifth Third Bancorp lifted its position in Takeda Pharmaceutical by 85.5% during the first quarter. Fifth Third Bancorp now owns 5,232 shares of the company's stock valued at $78,000 after purchasing an additional 2,411 shares during the last quarter. Simon Quick Advisors LLC purchased a new position in shares of Takeda Pharmaceutical in the 1st quarter worth $164,000. GAMMA Investing LLC increased its holdings in shares of Takeda Pharmaceutical by 22.6% in the 1st quarter. GAMMA Investing LLC now owns 7,042 shares of the company's stock worth $105,000 after buying an additional 1,296 shares during the last quarter. Finally, Farther Finance Advisors LLC increased its holdings in shares of Takeda Pharmaceutical by 29.2% in the 1st quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company's stock worth $69,000 after buying an additional 1,045 shares during the last quarter. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Trading Down 1.0%

Shares of NYSE TAK traded down $0.16 during midday trading on Friday, hitting $14.75. The company's stock had a trading volume of 1,360,811 shares, compared to its average volume of 1,946,678. Takeda Pharmaceutical Co. has a 12-month low of $12.58 and a 12-month high of $15.68. The company has a current ratio of 1.01, a quick ratio of 0.52 and a debt-to-equity ratio of 0.57. The firm has a market cap of $46.92 billion, a P/E ratio of 67.03 and a beta of 0.23. The business's 50 day moving average is $14.77 and its two-hundred day moving average is $14.20.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.08). The business had revenue of $7.34 billion for the quarter, compared to the consensus estimate of $8.02 billion. Takeda Pharmaceutical had a return on equity of 10.64% and a net margin of 2.36%. As a group, equities research analysts expect that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.